Skip to main content
48°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biovaxys Technology Corp
(CSE:
BIOV
)
0.0700
UNCHANGED
Streaming Delayed Price
Updated: 3:48 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biovaxys Technology Corp
< Previous
1
2
Next >
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
September 20, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
BioVaxys Technology Corp. to Present at the Life Sciences Investor Forum September 19th 2024
September 17, 2024
BioVaxys invites individual and institutional investors, as well as advisors and analysts, to attend online at www.VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
September 16, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
The Power Play by The Market Herald Releases New Interviews with Reunion Gold Corp, Numinus Wellness, Core Assets, Blockmate Ventures, BioVaxys Tech, Carlyle Commodities and Belmont Resources Discussing Their Latest News
April 18, 2023
Via
ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with Spey Resources, Melkior Resources and BioVaxys Technology Discussing Their Latest News
March 16, 2023
Via
ACCESSWIRE
The Power Play by The Market Herald Releases New Interviews with ApartmentLove, Sirios Resources, Aton Resources, Mountain Boy Minerals and BioVaxys Technology Discussing Their Latest News
December 20, 2022
Via
ACCESSWIRE
BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine
December 01, 2022
Vancouver, BC – December 1, 2022 – BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or “Company”) is pleased to announce the successful sterile and bacteria-free test-run...
Via
FinancialNewsMedia
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
December 01, 2022
EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
The Power Play by The Market Herald Releases New Interviews with RDARS, Infinity Stone Ventures, BioVaxys Technology, and Sitka Gold Discussing Their Latest News
October 06, 2022
Via
ACCESSWIRE
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
October 06, 2022
Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing...
Via
FinancialNewsMedia
BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps
October 06, 2022
Agreement Includes Right of First Refusal in the US for Ovosicare and Libicare Vancourver, BC – October 6, 2022 – BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or...
Via
FinancialNewsMedia
The Power Play by The Market Herald Releases a New Interview with BioVaxys Technology Discussing Their Latest News
September 28, 2022
Via
ACCESSWIRE
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression
May 18, 2022
Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past 30...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement
May 18, 2022
Vancouver, BC – May 18, 2022 — BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or “Company”), announced today that Hospices Civils de Lyon, France (“HCL”) has agreed to...
Via
FinancialNewsMedia
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
April 25, 2022
Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer...
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction
April 25, 2022
Vancouver, BC – April 25, 2022 — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has entered into an agreement with the Deaconess Research...
Via
FinancialNewsMedia
Topics
Economy
Exposures
Supply Chain
The Power Play by The Market Herald Releases Interviews With Monarch Mining, Vox, Tocvan Ventures, GeneTether Therapeutics, Peloton Minerals, SWMBRD Sports, and BioVaxys Technology Corp.
March 30, 2022
VANCOUVER, BC / ACCESSWIRE / March 30, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Monarch Mining, Vox, Tocvan Ventures, GeneTether Therapeutics, Peloton...
From
The Market Herald
Via
AccessWire
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
March 24, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2022 – USA News Group – Whenever a new COVID-19 variant emergences, health authorities have had limited options to fight...
Via
FinancialNewsMedia
Exposures
COVID-19
Biotech Sector’s Response to Omicron Panic Should be Swift and Effective
December 07, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC – December 7, 2021 – USA News Group – Despite a level of panic that JP Morgan has already downplayed in its 2022 forecasts, the...
Via
FinancialNewsMedia
Exposures
COVID-19
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
December 07, 2021
Palm Beach, FL – December 7, 2021 – FinancialNewsMedia.com News Commentary There are many unknowns surrounding the new omicron Covid variant; there are early signs it’s more transmissible, but it’s not...
Via
FinancialNewsMedia
Exposures
COVID-19
Covid-19 Test Shortage Emphasized by New $70M Plan to Speed Up Authorizations
November 09, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 9, 2021 – USA News Group – New at-home Covid tests are on the way, according to the Biden administration, which announced...
Via
FinancialNewsMedia
Exposures
COVID-19
Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030
November 09, 2021
Palm Beach, FL – November 9, 2021 – FinancialNewsMedia.com News Commentary – The increasing outbreak of covid-19 is increasing the demand for coronavirus vaccines or therapies, which will result in the...
Via
FinancialNewsMedia
Topics
Death
Exposures
COVID-19
Death
BioVaxys announces that CoviDTH Demonstrates Safety and Tolerability in Broad Ranging In Vivo Clinical Pathology, Immunology, and Histopathology Evaluation, Supporting Planned Clinical Development of CoviDTH
November 09, 2021
VANCOUVER, BC – November 9, 2021 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today that results from its in vivo animal research study support...
Via
FinancialNewsMedia
Faster, Cheaper, More Reliable COVID-19 Tests Needed for the Unprecedented Demand Ahead
October 20, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC –October 20, 2021 – USA News Group – It may have its beginning for the UK travel industry, but there are signs of the end of using...
Via
FinancialNewsMedia
Exposures
COVID-19
BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine
October 20, 2021
Vancouver, BC – October 20, 2021 – BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) (FRA:5LB) (“BioVaxys” or “Company”) announced today that it has filed with the United States Patent & Trademark...
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
Scientific Reports Revealing Early Promise for Universal Coronavirus Vaccine
October 20, 2021
Palm Beach, FL – October 20, 2021 – FinancialNewsMedia.com News Commentary – Recently, scientific reports have shown that a universal coronavirus vaccine that protects against COVID-19 causing...
Via
FinancialNewsMedia
Exposures
COVID-19
New Covid-19 Vaccines Continue to Be Developed by Biotech Firms Seeking to Improve the Jab
October 06, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC –October 6, 2021 – USA News Group – As vaccine passport programs continue to roll out in new markets across the globe, especially in...
Via
FinancialNewsMedia
Exposures
COVID-19
Big Changes Coming to Covid Testing in Response to Rising Demand Under Latest Mandates
September 28, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Why Some Experts Say for an Effective COVID Vaccine, Look Beyond Antibodies to T-Cells
September 28, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
BIOVAXYS BEGINS TOXICITY STUDY AHEAD OF COVIDTH IND SUBMISSION
September 28, 2021
Via
FinancialNewsMedia
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.